Apoptosis mediated regression of transplantable LS lymphosarcoma in CBA mice treated with ACVP (adriamycin, cyclophosphamide, vincristine, prednisolone) or cyclophosphamide alone
Kaledin, V.I.; Nikolin, V.P.; Timofeeva, O.A.; Filipenko, M.L.; Baymak, T.Y.; Galyamova, M.R.; Popova, N.A.
Eksperimental'naya Onkologiya 24(1): 55-58
2002
ISSN/ISBN: 0204-3564 Accession: 010193860
The antitumor activity of a four-drug combination, cyclophosphamide (CP), adriamycin, vincristine, and prednisolone, was studied on a transplantable lymphosarcoma LS in CBA mice. A single injection of the drug mixture produced a complete regression of the tumor transplants in all animals. The effect was found to be elicited by CP, not by any other constituent of the mixture. Morphological analyses of tumor slices and DNA electrophoresis evidenced that tumors regressed by apoptosis.
PDF emailed within 1 workday: $29.90
Related References
Bezwoda, W.R.; Rastogi, R.B. 1994: A randomized comparative study of cyclophosphamide, vincristine, doxorubicin, and prednisolone and cyclophosphamide, vincristine, mitoxantrone, and prednisolone regimens in the treatment of intermediate- and high-grade lymphoma with 8 years' follow-up Seminars in Hematology 31(2 Suppl 3: 3Kolarić, K.; Roth, A.; Vukas, D.; Cervek, J. 1984: CAP (cyclophosphamide, adriamycin, platinum) vs CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisolone) combination chemotherapy in untreated metastatic breast cancer. A preliminary report of a controlled clinical study Cancer ChemoTherapy and Pharmacology 13(2): 142-144
Walewski, J.A. 1983: Induction of remission in patients with non-Hodgkin lymphomas with high degree of malignancy - preliminary comparison of 2 chemotherapy programs: CHOP-B (cyclophosphamide, adriamycin, vincristine, encorton, bleomycin) and MEV-A (methotrexate, cyclophosphamide, vincristine and adriamycin) Nowotwory 33(3): 259-265
Goodman, G.E.; Blasko, J. 1986: Concurrent chemotherapy with vf 16 vincristine adriamycin cyclophosphamide vs. alternating chemotherapy with vp 16 cisplatinum and vincristine adriamycin cyclophosphamide in limited cell lung cancer a southwest oncology group study Proceedings American Society of Clinical Oncology Annual Meeting 5: 169
Abdyldaev, R.A.; Kruglova, G.V. 1984: Results of combination chemotherapy of lymphosarcoma with cyclophosphamide vincristine and prednisolone Journal of Soviet Oncology 5(3): 236-238
Abdyldaev, R.A.; Kruglova, G.V. 1983: Results of combined chemotherapy of lymphosarcoma with cyclophosphamide, vincristine and prednisolone Voprosy Onkologii 29(4): 83-85
Hagberg, H.; Bjorkholm, M.; Glimelius, B.; Lindemalm, C.; Mellstedt, H.; Killander, A. 1985: Cyclophosphamide adriamycin vincristine and prednisone vs. methotrexate cyclophosphamide and vincristine for the treatment of non hodgkins lymphoma of unfavorable histopathology a randomized clinical trial European Journal of Cancer and Clinical Oncology 21(2): 175-180
Shimizu K.; Kamiya O.; Hamajima N.; Mizuno H.; Kobayashi M.; Hirabayashi N.; Takeyama H.; Kato R.; Kawashima K.; Et Al 1990: Multi drug combination therapy with vincristine melphalan cyclophosphamide prednisolone was more effective than cyclophosphamide prednisolone in stage iii myeloma Japanese Journal of Cancer Research 81(12): 1320-1326
Kazuyuki Shimizu; Osamu Kamiya; Nobuyuki Hamajima; Harumitsu Mizuno; Masahide Kobayashi; Noriyuki Hirabayashi; Hideo Takeyama; Ryoichi Kato; Kohei Kawashima; Masakazu Nitta; Tomomitsu Hotta; Makoto Utsumi; Eiichi Nagura 1990: Multi-drug Combination Therapy with Vincristine-Melphalan-Cyclophosphamide-Prednisolone Was More Effective than Cyclophosphamide-Prednisolone in Stage III Myeloma Cancer Science 81(12): 1320-1327
Krommer, C.F.; Szalai, J.P. 1992: Cyclophosphamide, adriamycin and cisplatin (CAP) versus cyclophosphamide, adriamycin and vincristine (CAV) in the treatment of advanced ovarian cancer : a randomized study Annals of Oncology 3(1): 37-39
Salzer, H.; Gitsch, E.; Dittrich, C.; Sevelda, P.; Karrer, K.; Schemper, M.; Stempel-Smekal, G.; Langer, M.; Wagner, G.; Rainer, H. 1985: Results of the first Austrian multicenter ovarian cancer study: prospective randomized comparison of sequential chemotherapy (adriamycin/cisplatin--vincristine/cyclophosphamide--methotrexate) with 2 standard protocols (adriamycin/cyclophosphamide or adriamycin/cisplatin) in stage IIi and IV patients Geburtshilfe und Frauenheilkunde 45(11): 761-768
Kumagai, K.; Takagi, T.; Sakai, C.; Wakatsuki, S. 1996: Alternating chemotherapy with cyclophosphamide, adriamycin, vincristine and prednisolone (CHOP); etoposide, procarbazine, vindesine and prednisolone (EPVP) as a treatment for advanced-stage Hodgkin's disease Gan to Kagaku Ryoho. Cancer and ChemoTherapy 23(4): 499-501
Schoenfeld, D.A.; Rosenbaum, C.; Horton, J.; Wolter, J.M.; Falkson, G.; DeConti, R.C. 1982: A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma Cancer 50(12): 2757-2762
Saaki, A.; Yokomatsu, Y.; Kojima, K.; Yoshikawa, T.; Sannomiya, Y.; Tatsumi, J.; Hashimoto, K.; Park, K.; Kawarabayashi, K.; Yoshikawa, C. 1986: Combination chemotherapy with cyclophosphamide, adriamycin, vincristine and prednisolone (VEPA) for non-Hodgkin's lymphoma Gan to Kagaku Ryoho. Cancer and ChemoTherapy 13(1): 65-69
Fridrik, M.A.; Jaeger, U.; Petzer, A.; Willenbacher, W.; Keil, F.; Lang, A.; Andel, J.; Burgstaller, S.; Krieger, O.; Oberaigner, W.; Sihorsch, K.; Greil, R. 2016: Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: a randomised phase-IIi study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14) European Journal of Cancer 58: 112-121
Shimizu, K.; Kamiya, O.; Hamajima, N.; Mizuno, H.; Kobayashi, M.; Hirabayashi, N.; Takeyama, H.; Kato, R.; Kawashima, K.; Nitta, M. 1990: Multi-drug combination therapy with vincristine-melphalan-cyclophosphamide-prednisolone was more effective than cyclophosphamide-prednisolone in stage IIi myeloma. the Nagoya Myeloma Cooperative Study Group Japanese Journal of Cancer Research: Gann 81(12): 1320-1327
Arndt, C.A.S.; Stoner, J.A.; Hawkins, D.S.; Rodeberg, D.A.; Hayes-Jordan, A.A.; Paidas, C.N.; Parham, D.M.; Teot, L.A.; Wharam, M.D.; Breneman, J.C.; Donaldson, S.S.; Anderson, J.R.; Meyer, W.H. 2009: Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803 Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 27(31): 5182-5188
Hong, W.K.; Nicaise, C.; Lawson, R.; Maroun, J.A.; Comis, R.; Speer, J.; Luedke, D.; Hurtubise, M.; Lanzotti, V.; Goodlow, J. 1989: Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 7(4): 450-456
Chen, Y.-B.; Hochberg, E.P.; Feng, Y.; Neuberg, D.; Rawal, B.; Motyckova, G.; Fisher, D.C.; McAfee, S.L.; Spitzer, T.R.; Lacasce, A.S. 2010: Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vincristine, and prednisone Leukemia and Lymphoma 51(5): 789-796
Sampi, K.; Honda, T.; Hattori, M.; Takayama, S. 1983: Cyclophosphamide, adriamycin, vincristine, bleomycin and prednisolone (CHOP-Bleo) combination chemotherapy for advanced non-Hodgkin's lymphoma Gan to Kagaku Ryoho. Cancer and ChemoTherapy 10(5): 1266-1271